Protocol Library - Altai Oncology Software

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions

Over 1,000 cancer treatment protocols

Medical Oncology, Hematology, Bone Marrow Transplantation

With administration details, lab parameters, indications, and summarized references

Updated monthly to include latest approvals and major papers

Reviewed by Medical Oncologists and Hematologists

Soft Tissue Sarcoma

New Indication: Selinexor for Advanced Dedifferentiated Liposarcoma

Ulas D. Bayraktar, MD

Diffuse Large B Cell Lymphoma

New Drug: Glofitamab for Large B Cell Lymphoma

Ulas D. Bayraktar, MD

Multiple Myeloma

New Drug: Talquetamab for Multiple Myeloma

Ulas D. Bayraktar, MD

Chronic Lymphocytic Leukemia

New Reference: Obinutuzumab, ibrutinib, and venetoclax for Untreated CLL

Ulas D. Bayraktar, MD

Multiple Myeloma

New Indication: Isatuximab, Carfilzomib, Lenalidomide, Dexamethasone for Untreated High-Risk Multiple Myeloma

Ulas D. Bayraktar, MD

Follicular Lymphoma

New Indication: Zanubrutinib and Obinutuzumab for R/R Follicular Lymphoma

Ulas D. Bayraktar, MD

Uterine Cancer

New Indication: Selinexor for Maintenance in Advanced Endometrial Cancer

Ulas D. Bayraktar, MD

Non-Small Cell Lung Cancer

New Indication: Trastuzumab Deruxtecan for her2 Mutant NSCLC

Ulas D. Bayraktar, MD

Biliary Tract Cancer

New Reference: Erdafitinib for Advanced Solid Tumors with FGFR Alterations

Ulas D. Bayraktar, MD

Soft Tissue Sarcoma

New Indication: Selinexor for Advanced Dedifferentiated Liposarcoma

Phase II-III, multicenter, randomized, double-blind, placebo-controlled study (SEAL) Advanced dedifferentiated liposarcoma who received 2-5 lines chemotherapy Selinexor (N: 188) or

Diffuse Large B Cell Lymphoma

New Drug: Glofitamab for Large B Cell Lymphoma

Phase 2 study Relapsed or refractory DLBCL, transformed follicular lymphoma, high-grade B-cell lymphoma, or primary mediastinal large B-cell lymphoma Obinituzumab and Glofitamab (n

Multiple Myeloma

New Drug: Talquetamab for Multiple Myeloma

Multicenter, open-label, single-arm trial Adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibit

Chronic Lymphocytic Leukemia

New Reference: Obinutuzumab, ibrutinib, and venetoclax for Untreated CLL

Phase II, open label, multicenter (CLL-2-Give) Previously untreated patients with high-risk chronic lymphocytic leukemia (CLL) with del(17p) and/or TP53 mutation GIVe (Venetoclax +

Multiple Myeloma

New Indication: Isatuximab, Carfilzomib, Lenalidomide, Dexamethasone for Untreated High-Risk Multiple Myeloma

Phase II, non-randomised, multicenter (GMMG-CONCEPT) Newly diagnosed multiple myeloma (NDMM) with exclusively high-risk disease Arm A: Isa-KRd followed by ASCT followed İsa-KRd (T

Follicular Lymphoma

New Indication: Zanubrutinib and Obinutuzumab for R/R Follicular Lymphoma

Phase II, randomised (ROSEWOOD) Relapsed/refractory (R/R) follicular lymphoma (FL), who had ≥2 lines therapy Zanubritinib +Obinutuzumab (n=145) vs. Obinutuzumab (n=72)

New Indication: Selinexor for Maintenance in Advanced Endometrial Cancer

Phase III, randomised, prospective, multicenter double-blind, placebo-controlled study (ENGOT-EN5/GOG-3055/SIENDO) Patients 18 years or older with histologically confirmed EC, who

Non-Small Cell Lung Cancer

New Indication: Trastuzumab Deruxtecan for her2 Mutant NSCLC

Multicenter, blinded, phase 2 study Previously treated (platinum-containing therapy) patients with HER2m mNSCLC Trastuzumab deruxtecan: 5.4 mg/kg (n=102) vs. 6.4 mg/kg (n=52)

Biliary Tract Cancer

New Reference: Erdafitinib for Advanced Solid Tumors with FGFR Alterations

Phase II, single-arm, multicohort (RAGNAR) Patients aged 12 years or older with advanced or metastatic tumours of any histology (except urothelial cancer) with predefined FGFR1–4

Our Solutions

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols

Altai Oncology Suite

Our premiere, CE-marked, Windows application designed for cancer centers

Altai Oncology App

Easiest access to our protocol library on your hands

Altai Chemo Planner

Core features of Altai Oncology Suite for the solo Oncologist/Hematologist

Articles

Computerized Chemotherapy Order Entry

The Power of a Protocol Library: Standardizing Oncology Care Across Institutions

Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …

From Protocol to Pharmacy: Ensuring Seamless Chemotherapy Order Handover

Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.

Back to top Drag